Free Trial

FibroGen (FGEN) Stock Price, News & Analysis

FibroGen logo
$5.25 -0.02 (-0.38%)
Closing price 04:00 PM Eastern
Extended Trading
$5.56 +0.31 (+5.81%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About FibroGen Stock (NASDAQ:FGEN)

Key Stats

Today's Range
$5.20
$5.70
50-Day Range
$5.16
$8.61
52-Week Range
$4.50
$38.25
Volume
71,456 shs
Average Volume
76,554 shs
Market Capitalization
$21.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$250.00
Consensus Rating
Moderate Buy

Company Overview

FibroGen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

FGEN MarketRank™: 

FibroGen scored higher than 93% of companies evaluated by MarketBeat, and ranked 162nd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    FibroGen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    FibroGen has only been the subject of 1 research reports in the past 90 days.

  • Read more about FibroGen's stock forecast and price target.
  • Earnings Growth

    Earnings for FibroGen are expected to grow in the coming year, from ($0.80) to ($0.45) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of FibroGen is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of FibroGen is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about FibroGen's valuation and earnings.
  • Percentage of Shares Shorted

    5.10% of the float of FibroGen has been sold short.
  • Short Interest Ratio / Days to Cover

    FibroGen has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in FibroGen has recently decreased by 94.83%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    FibroGen does not currently pay a dividend.

  • Dividend Growth

    FibroGen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.10% of the float of FibroGen has been sold short.
  • Short Interest Ratio / Days to Cover

    FibroGen has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in FibroGen has recently decreased by 94.83%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    FibroGen has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for FibroGen this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for FGEN on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added FibroGen to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, FibroGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $119,485.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 1.98% of the stock of FibroGen is held by insiders.

  • Percentage Held by Institutions

    72.71% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about FibroGen's insider trading history.
Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Stock News Headlines

FibroGen Inc.
FibroGen (NASDAQ:FGEN) Raised to "Hold" at Wall Street Zen
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
FibroGen Enters Relicensing Agreement with HiFiBiO
FibroGen Announces 1-for-25 Reverse Stock Split
See More Headlines

FGEN Stock Analysis - Frequently Asked Questions

FibroGen's stock was trading at $13.2375 at the start of the year. Since then, FGEN stock has decreased by 60.3% and is now trading at $5.25.
View the best growth stocks for 2025 here
.

FibroGen, Inc (NASDAQ:FGEN) announced its earnings results on Monday, May, 12th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.75 by $4.75. The biopharmaceutical company earned $2.70 million during the quarter, compared to the consensus estimate of $2 million.
Read the conference call transcript
.

FibroGen shares reverse split before market open on Tuesday, June 17th 2025.The 1-25 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

FibroGen (FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that FibroGen investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/12/2025
Today
7/02/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FGEN
Employees
570
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$250.00
High Stock Price Target
$250.00
Low Stock Price Target
$250.00
Potential Upside/Downside
+4,449.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$47.58 million
Pretax Margin
-117.74%

Debt

Sales & Book Value

Annual Sales
$29.62 million
Price / Cash Flow
N/A
Book Value
($50.89) per share
Price / Book
-0.11

Miscellaneous

Free Float
3,962,000
Market Cap
$22.20 million
Optionable
Optionable
Beta
0.74

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:FGEN) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners